Details

Autor(en) / Beteiligte

• Chapman, Paul B
• Hauschild, Axel
• Robert, Caroline
• Haanen, John B
• Ascierto, Paolo
• Larkin, James
• Dummer, Reinhard
• Garbe, Claus
• Testori, Alessandro
• Maio, Michele
• Hogg, David
• Lorigan, Paul
• Lebbe, Celeste
• Jouary, Thomas
• Schadendorf, Dirk
• Ribas, Antoni
• O'Day, Steven J
• Sosman, Jeffrey A
• Kirkwood, John M
• Eggermont, Alexander M.M
• Dreno, Brigitte
• Nolop, Keith
• Li, Jiang
• Nelson, Betty
• Hou, Jeannie
• Lee, Richard J
• Flaherty, Keith T
• McArthur, and Grant A

Titel

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Ist Teil von

• The New England journal of medicine, 2011-06, Vol.364 (26), p.2507-2516

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• In patients with advanced melanomas with the BRAF V600E mutation, vemurafenib produced a response in nearly half the patients; secondary skin tumors, arthralgia, rash, and fatigue were side effects. Dacarbazine produced a response in 6%. Metastatic melanoma has a poor prognosis, with the median survival for patients with stage IV melanoma ranging from 8 to 18 months after diagnosis, depending on the substage. 1 In the United States last year, 8700 deaths from melanoma were projected, with an estimated rate of death of 2.6 in 100,000. 2 Rates of death from melanoma in Australia and New Zealand are slightly higher (3.5 in 100,000), whereas rates in Western Europe are slightly lower (1.8 in 100,000). 3 In phase 3 studies, dacarbazine, the only chemotherapeutic agent approved by the Food and Drug Administration for the treatment of metastatic melanoma, was . . .